- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026 | 2 | Cision News | ||
| 07.11. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports third quarter 2025 | 1 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.11. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 3 | Cision News | ||
| 29.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | 1 | Cision News | ||
| 21.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2 | 1 | Cision News | ||
| 17.10. | BIO-WORKS TECHNOLOGIES AB: Correction: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 4 | Cision News | ||
| 17.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 1 | Cision News | ||
| 16.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11 | 1 | Cision News | ||
| 08.10. | BIO-WORKS TECHNOLOGIES AB: Strong interest in WorkBeads affimAb Edge: Next-Generation Protein A Resin for Antibody Purification | 3 | Cision News | ||
| 07.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies wins appeal against the Swedish Tax Agency in the Supreme Administrative Court | 2 | Cision News | ||
| 01.10. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the fourth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 20.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Launches WorkBeads affimAb Edge: Strategic Expansion in the Protein A Resin Market | 1 | Cision News | ||
| 19.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders have informed of their intention to exercise all their Warrants TO2 | 1 | Cision News | ||
| 14.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB will be publishing the Q2 interim report 2025 tomorrow Friday the 15'th of August | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 3 of 11 | 1 | Cision News | ||
| 11.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives SEK 5.5 Million Order from Global Pharmaceutical Company | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the third exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 1,050 | +3,96 % | Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025 | ||
| GALECTO | 27,400 | 0,00 % | Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| JYONG BIOTECH | 3,175 | 0,00 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,520 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | 0,00 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | 0,00 % | Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) | ||
| TAYSHA GENE THERAPIES | 5,490 | 0,00 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| RELAY THERAPEUTICS | 8,400 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| IMMUNEERING | 5,650 | 0,00 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | 0,00 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | 0,00 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,200 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.